6 results about "Diacerein" patented technology

The present invention relates to the process for the preparation of topical formulations of anthraquinone compound. The present invention specifically relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of ointment, cream, gel and transferosomal gel. The present invention more specifically relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of ointment, cream, gel comprising the steps of heating, adding, stirring, dissolving and mixing. The present invention also relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of transferosomal gel comprising the steps of thin film formation, hydration of thin film and transferosomal gel formation. The present invention also relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of transferosomal gel comprising the steps of dissolving, adding and mixing.

1. Name of the product in this design: Packaging Box (Joint Version of Diacerein Capsules). 2. Purpose of this design: This design is intended for use as outer packaging for pharmaceuticals. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention provides a candidate medicine for promoting the embryo implantation efficiency of an endometritis type RIF patient, and belongs to the technical field of embryo implantation. In order to solve the problem of how to discover potential intervention drugs aiming at the endometritis type RIF pathological mechanism, a five-step efficient drug screening strategy based on an in-vitro implantation model of the endometritis type RIF is adopted, so that the reliability and function correlation of a screening result are ensured. According to the invention, a candidate drug screened by adopting a five-step method efficient drug screening strategy comprises any one of the following drugs: evocamide, choline, nitrendipine, megestrol acetate, pranoprofen, oxaliplatin, adenine, ensorizole, baicalin and diacerein. Evocamide, choline and nitrendipine in the candidate drugs are three drugs with the best implantation promotion efficiency for patients with endometritis type RIF.

1. Name of the product in this design: Diacerein Capsule Packaging Box (Molecular Version). 2. Purpose of this design: This design is intended for use as outer packaging for pharmaceuticals. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention belongs to the technical field of medicinal chemistry, and discloses a novel diacerein crystal form and a preparation method thereof. The X-ray powder diffraction pattern of the novel crystal form shows characteristic diffraction peaks when the angle 2 theta is 5.18 degrees + / -0.2 degrees, 10.42 degrees + / -0.2 degrees, 17.38 degrees + / -0.2 degrees, 21.45 degrees + / -0.2 degrees, 21.86 degrees + / -0.2 degrees, 25.07 degrees + / -0.2 degrees and 27.85 degrees + / -0.2 degrees. Stability tests show that the novel crystal form has excellent stability and solubility, is beneficial to drug absorption and curative effect exertion, and can be applied to preparation of diacerein drugs. The preparation method comprises the following steps: mixing a diacerein crude product with N-methyl pyrrolidone, heating at 90-100 DEG C until the diacerein crude product is completely dissolved, adding acetone or ethanol, and crystallizing to obtain the target new crystal form. The preparation process is simple, convenient and efficient to operate, large-scale production is easy to realize, and a new choice is provided for production and application of diacerein drugs.

The present application discloses a rhein-piperazine-sulfamide hybrid and a preparation method and application thereof. The rhein-piperazine-sulfamide hybrid is a compound shown in formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 is selected from hydrogen or acetyl; R 2 is selected from aryl or heteroaryl which is unsubstituted or substituted with alkyl, alkoxy, halogen or nitro. The present application combines rhein or diacerein as a starting material, piperazine as a linking group, and a sulfamide derivative into one molecule, to obtain an anticancer candidate drug which is more active, more selective and safer than the parent rhein.